224 related articles for article (PubMed ID: 27680012)
21. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence.
Sueta A; Yamamoto Y; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Iwase H
Oncotarget; 2017 Sep; 8(41):69934-69944. PubMed ID: 29050253
[TBL] [Abstract][Full Text] [Related]
23. Tuberous sclerosis complex.
Islam MP; Roach ES
Handb Clin Neurol; 2015; 132():97-109. PubMed ID: 26564073
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
25. Potential miRNA involvement in the anti-adipogenic effect of resveratrol and its metabolites.
Eseberri I; Lasa A; Miranda J; Gracia A; Portillo MP
PLoS One; 2017; 12(9):e0184875. PubMed ID: 28953910
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
28. Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy.
Wheless JW
Epilepsy Behav Case Rep; 2015; 4():63-6. PubMed ID: 26543807
[TBL] [Abstract][Full Text] [Related]
29. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
Appalla D; Depalma A; Calderwood S
Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway.
Shen L; Sun C; Li Y; Li X; Sun T; Liu C; Zhou Y; Du Z
Tumour Biol; 2015 Sep; 36(9):6929-38. PubMed ID: 25854175
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature.
Tran LH; Zupanc ML
Pediatr Neurol; 2015 Jul; 53(1):23-30. PubMed ID: 26092412
[TBL] [Abstract][Full Text] [Related]
32. Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: a lung cancer study.
Mitra R; Lin CC; Eischen CM; Bandyopadhyay S; Zhao Z
RNA; 2015 Jun; 21(6):1055-65. PubMed ID: 25852169
[TBL] [Abstract][Full Text] [Related]
33. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
34. Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
Zhang S; Ouyang X; Jiang X; Gu D; Lin Y; Kong SK; Xie W
Int J Med Sci; 2015; 12(7):590-8. PubMed ID: 26283876
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
[TBL] [Abstract][Full Text] [Related]
36. MiR-100-5p, miR-199a-3p and miR-199b-5p induce autophagic death of endometrial carcinoma cell through targeting mTOR.
Cai J; Zhang Y; Huang S; Yan M; Li J; Jin T; Bao S
Int J Clin Exp Pathol; 2017; 10(9):9262-9272. PubMed ID: 31966798
[TBL] [Abstract][Full Text] [Related]
37. Tuberous sclerosis in a 19-week fetus: immunohistochemical and molecular study of hamartin and tuberin.
Wei J; Li P; Chiriboga L; Mizuguchi M; Yee H; Miller DC; Greco MA
Pediatr Dev Pathol; 2002; 5(5):448-64. PubMed ID: 12202993
[TBL] [Abstract][Full Text] [Related]
38. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
39. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs relate to early worsening of renal function in patients with acute heart failure.
Bruno N; ter Maaten JM; Ovchinnikova ES; Vegter EL; Valente MA; van der Meer P; de Boer RA; van der Harst P; Schmitter D; Metra M; O'Connor CM; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JG; Givertz MM; Bloomfield DM; Dittrich HC; Pinto YM; van Veldhuisen DJ; Hillege HL; Berezikov E; Voors AA
Int J Cardiol; 2016 Jan; 203():564-9. PubMed ID: 26569364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
